$GOSS

Schall Law Firm launches class action against Gossamer Bio for allegedly making false statements about Phase 3 PROSERA study design and placebo response controls.

Rosen Law Firm urges Gossamer Bio investors to meet June 1 securities lawsuit deadline, alleging concealed Phase 3 trial design flaws while making positive statements.

Rosen Law Firm alerts $GOSS investors of June 1 deadline to join securities class action over alleged Phase 3 study discrepancies.

Rosen Law Firm sues $ZSPC for allegedly concealing preferred shareholder information and litigation risks in registration statement. Investors face deadline to join.

Gossamer Bio ($GOSS) faces class action lawsuit after Phase 3 trial failure caused 80% stock plunge. Investors allege management misled them about trial design despite knowing of critical issues.

Rosen Law Firm sues Gossamer Bio ($GOSS) over alleged misstatements about Phase 3 trial design. Lead plaintiff deadline: June 1, 2026.

Class action lawsuit filed against Gossamer Bio for allegedly concealing design flaws in Phase 3 PROSERA study, claiming investors purchased stock at artificially inflated prices.

Rosen Law Firm filed class action against Gossamer Bio alleging false statements about Phase 3 PROSERA study design. Eligible investors must act before deadline.

Rosen Law Firm files class action against zSpace Inc. ($ZSPC) for alleged securities fraud involving misstatements about preferred shareholder obligations and litigation risks. June 22, 2026 deadline for lead plaintiff motions.

Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.

Law Offices of Howard G. Smith initiates securities fraud class actions against $PINS, $NUAI, $GOSS, and $MEDP; investors have until May-June 2026 deadline for lead plaintiff motions.

Class action lawsuit filed against Gossamer Bio alleging material misstatements regarding Phase 3 PROSERA study results and hidden design flaws at Latin American test sites.

Class action lawsuit filed against Gossamer Bio for alleged false statements regarding Phase 3 PROSERA study results and concealed trial design issues at Latin American sites.

Aquestive Therapeutics faces class action lawsuit alleging securities fraud over false FDA approval statements and concealed anaphylaxis product risks.

Coty Inc. faces securities fraud lawsuit alleging misleading growth guidance before 22% stock plunge. Law firm seeks class action damages.

Gossamer Bio faces securities fraud lawsuit after stock plummets 80% following disclosure of allegedly undisclosed Latin American trial site enrollment practices that compromised Phase 3 study results. Lead plaintiff deadline is June 1, 2026.

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.

Law firm Holzer & Holzer filed shareholder class actions against $NUAI and $GOSS for allegedly making materially false statements. Investors have until June 1, 2026 to seek lead plaintiff status.

Gossamer Bio ($GOSS) faces class action lawsuit over failed PROSERA PAH trial; stock crashed 80% to $0.42 per share on February 23, 2026, amid allegations of misleading investor statements.

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.